Wall Street analysts expect that Patheon NV (NASDAQ:PTHN) will announce $520.43 million in sales for the current quarter, according to Zacks. Eight analysts have provided estimates for Patheon NV’s earnings, with the lowest sales estimate coming in at $502.70 million and the highest estimate coming in at $530.00 million. Patheon NV posted sales of $482.00 million during the same quarter last year, which suggests a positive year-over-year growth rate of 8%. The firm is expected to report its next quarterly earnings results on Monday, January 1st.
On average, analysts expect that Patheon NV will report full year sales of $520.43 million for the current fiscal year, with estimates ranging from $1.99 billion to $2.02 billion. For the next fiscal year, analysts expect that the company will post sales of $2.20 billion per share, with estimates ranging from $2.18 billion to $2.23 billion. Zacks Investment Research’s sales averages are an average based on a survey of analysts that follow Patheon NV.
Patheon NV (NASDAQ:PTHN) last announced its quarterly earnings results on Thursday, June 8th. The company reported $0.20 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.19 by $0.01. The company had revenue of $483.40 million during the quarter, compared to analyst estimates of $466.08 million. The company’s revenue was up 3.2% on a year-over-year basis.
PTHN has been the topic of a number of research analyst reports. Jefferies Group LLC reaffirmed a “buy” rating and set a $32.00 price objective (down from $33.00) on shares of Patheon NV in a research report on Friday, March 17th. Zacks Investment Research raised shares of Patheon NV from a “hold” rating to a “buy” rating and set a $39.00 price objective on the stock in a research report on Friday, May 19th. Raymond James Financial, Inc. reaffirmed a “market perform” rating and set a $35.00 price objective on shares of Patheon NV in a research report on Thursday, June 8th. William Blair downgraded shares of Patheon NV from an “outperform” rating to a “market perform” rating in a research report on Monday, May 15th. Finally, Leerink Swann downgraded shares of Patheon NV from an “outperform” rating to a “market perform” rating and boosted their price objective for the company from $31.00 to $35.00 in a research report on Friday, June 9th. Eight analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Patheon NV currently has an average rating of “Hold” and a consensus price target of $33.05.
Hedge funds have recently bought and sold shares of the company. Goldman Sachs Group Inc. increased its stake in Patheon NV by 48.4% in the first quarter. Goldman Sachs Group Inc. now owns 100,293 shares of the company’s stock valued at $2,642,000 after buying an additional 32,718 shares in the last quarter. Redmile Group LLC increased its stake in Patheon NV by 87.6% in the first quarter. Redmile Group LLC now owns 826,843 shares of the company’s stock valued at $21,779,000 after buying an additional 386,123 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in Patheon NV during the first quarter valued at approximately $3,437,000. Citadel Advisors LLC increased its stake in Patheon NV by 20.8% in the first quarter. Citadel Advisors LLC now owns 434,403 shares of the company’s stock valued at $11,442,000 after buying an additional 74,912 shares in the last quarter. Finally, Lazard Asset Management LLC increased its stake in Patheon NV by 12.6% in the first quarter. Lazard Asset Management LLC now owns 111,575 shares of the company’s stock valued at $2,938,000 after buying an additional 12,475 shares in the last quarter.
Shares of Patheon NV (PTHN) traded up 0.06% during trading on Wednesday, hitting $34.84. 292,966 shares of the company’s stock were exchanged. Patheon NV has a 1-year low of $23.72 and a 1-year high of $34.94. The stock’s 50 day moving average is $32.21 and its 200 day moving average is $29.30. The firm has a market capitalization of $5.06 billion and a PE ratio of 44.67.
Patheon NV Company Profile
Patheon N.V. is a provider of outsourced pharmaceutical development and manufacturing services. The Company’s segments include Drug Product Services (DPS), Pharmaceutical Development Services (PDS) and Drug Substance Services (DSS). The DPS segment is engaged in manufacturing and packaging for approved prescription, over-the-counter (OTC) and nutritional products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2230868/patheon-nv-pthn-expected-to-announce-quarterly-sales-of-520-43-million.html
Receive News & Ratings for Patheon NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Patheon NV and related companies with MarketBeat.com's FREE daily email newsletter.